郭晓华,李俊萍,张昕,张格日乐

• 1:包头医学院第一附属医院心内科

摘要(Abstract)：

目的研究阿托伐他汀对急诊经皮冠状动脉介入治疗(PCI)术后对比剂肾病(CIN)的保护作用及其作用机制。方法入选158例急性ST段抬高心肌梗死行急诊PCI术的患者,随机分为强化剂量组(80例,术前给予阿托伐他汀80 mg)和常规剂量组(78例,术前给予阿托伐他汀20 mg),比较不同剂量阿托伐他汀治疗后患者血肌酸酐、尿素氮、肌酐清除率、CIN发生率、尿微量白蛋白、α1-微球蛋白、超氧化物歧化酶、丙二醛、C反应蛋白的变化。结果强化剂量组比常规剂量组术后血肌酸酐下降,肌酐清除率升高,血浆超氧化物歧化酶水平升高,而丙二醛、C反应蛋白、尿α1-微球蛋白水平降低(均P<0.05);尿微量白蛋白有下降趋势,但差异无统计学意义(P>0.05);强化剂量组对比剂肾病发生率低于常规剂量组(P<0.05)。结论急诊PCI术前强化阿托伐他汀治疗可降低对比剂肾病的发生率,其疗效与他汀剂量相关;阿托伐他汀可能通过抗炎、抗氧化应激作用来保护肾功能,减少对比剂肾病的发生。

关键词(KeyWords)： 经皮冠状动脉介入治疗;阿托伐他汀;对比剂肾病

Abstract:

Keywords:

基金项目(Foundation): 内蒙古自治区自然科学基金(2011MS1130)

作者(Author): 郭晓华,李俊萍,张昕,张格日乐

参考文献(References)：

• [1]Thomsen HS,European Society of Urogenital Radiology.European Society of Urogenital Radiology guidelines on contrast media application.Curr Opin Urol,2007,17:70-76.
• [2]Marenzi G,Lauri G,Assanelli E,et al.Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infaction.J Am Coll Cardiol,2004,44:1780-1785.
• [3]Senco T,Molohiro M,Kamihata H,et al.Contrast induced nephropathy in patientsundergoing emergency coronary intervention for acute coronary syndrome.Am J Cardiol,2010,105:624-628.
• [4]Zhang T,Shen LH,Hu LH,et al.Statins for the prevention of contrast-induced nephropathy:a systematic review and metaanalysis.Am J Nephrol,2011,33:344-351.
• [5]Ichiki T,Takeda K,Tokunou T,et al.Down regulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.Arterioscler Thromb Vasc Biol,2001,21:1896-1901.
• [6]Bonetti PO,Lerman LO,Napoli C,et al.Statin effects beyond lipid lowering-are they clinically relevant?Eur Heart J,2003,24:225-248.
• [7]豆亚静,陈晖,严松彪.对比剂肾病的研究进展.中华临床医师杂志:电子版,2012,6:1816-1818.
• [8]Toprak O.Risk markers for contrast-induced nephropathy.Am J Med Sci,2007,334:283-290.
• [9]Rundback JH,Nahl D,Yoo V.Contrasst-induced nephropathy.J Vasc Surg,2011,54:575-579.
• [10]Trivedi HS,Moore H,Nasr S,et al.A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.Nephron Clin Pract,2003,93:29-34.
• [11]Patti G,Ricottini E,Nusca A,et al.Short-term,high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes percutaneous coronary intervebtion from the ARMYDA-CIN trial.Am J Cardiol,2011,108:1-7.
• [12]Zhou Y,Yun WJ,Zhu N,et al.Short-term,high-dose statins in the prevention of contrast-induced nephropathy:a systematic review and meta-analysis.Clin Nephrol,2011,76:475-483.
• [13]Zhang T,Shen LH,Hu LH,et al.Statins for the prevention of contrast-induced nephropathy:a systematic review and metaanalysis.Am J Nephrol,2011,33:344-351.
• [14]刘勇,谭宁,陈玉怡,等.不同剂量阿托伐他汀对慢性肾病患者行冠脉介入治疗后对比剂肾病的影响.中国介入心脏病学杂志,2011,19:218-222.
• [15]Penders J,Delanghe JR.Alpha 1-microglobulin:clinical laboratory aspects and applications.Clin Chim Acta,2004,346:107-118.
• [16]Vyssousoulis GP,Tousoulis D,Antoniades C,et al.Alpha-1microglobulin as a new inflammatory markers in newly diagnosed hypertensive patients.Am J Hypertens,2007,20:1016-1021.
• [17]Patti G,Ricottini E,Nusca A,et al.Short-term,high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN trial.Am J Cardiol,2011,108:1-7.
• [18]Zhang T,Shen L H,Hu L H,et al.Statins for the prevention of contrast-induced nephropathy:a systematic review and metaanalysis.Am J Nephrol,2011,33:344-351.
• [19]Ichiki T,Takeda K,Tokunou T,et al.Downregulation of angiotensinⅡtype 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.Arterioscler Thromb Vasc Biol,2001,21:1896-1901.
• [20]Bonetti PO,Lerman LO,Napoli C,et al.Statin effects beyond lipid lowering-are they clinically relevant?Eur Heart J,2003,24:225-248.